Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter: Quinlynn Champ, PharmD Candidate Class of 2022, South College School of Pharmacy Dalia Elabed, PharmD Candidate 2022, University of South Florida Taneja College of Pharmacy Erica Hicks, PharmD Candidate 2022, South College School of Pharmacy Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022 Jessica Rogers, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Kevin Suarez, PharmD. Candidate, Creighton University, School of Pharmacy and Health Professions | 
We are all familiar with the triad of diseases expected in diabetes patients. As soon as someone is diagnosed, we start to worry about cardiovascular and renal problems. In addition, we often swing our prescribing for these patients to the SGLT-2 inhibitors, as they have proven to be both cardio and renal protective. But if these diabetes drugs can help with hypertension, then is it possible that hypertensive drugs like ACE’s and ARB’s can help with diabetes control or prevention?